Larimar Therapeutics, Inc. LRMR · SEC Filings

website

Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage ...

Price2.53

Market Cap266.29 M

Float82.49 M

CountryUS

SectorHealthcare

ExchangeNASDAQ

Overview Filings Insights Dilution News Transcripts

Search in Documents

Open in Studio Login

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

Financials

TYPE

HEADLINE

FILED AT

News

TYPE

HEADLINE

FILED AT

8-K

NEWLarimar Therapeutics Completes Rolling BLA Submission for Nomlabofusp in Friedreich’s Ataxia

Nov 9, 2026

8-K

Larimar Therapeutics Appoints John B. Harlow, Jr. as President and Chief Operating Officer

Sep 29, 2026

8-K

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

Aug 4, 2026

8-K

Larimar Therapeutics Submits First Module of Rolling BLA for Nomlabofusp and Reports Positive Long-Term Data in Friedreich’s Ataxia

Jun 29, 2026

8-K

Larimar Therapeutics, Inc. Announces Results of 2026 Annual Meeting of Stockholders

May 19, 2026

8-K

Larimar Therapeutics Reports Q1 2026 Financial Results and Progress Toward Nomlabofusp BLA Submission

May 14, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

REGISTERED OFFERING

Feb 26, 2026

424B5

PENDING FIXED PRICE OFFERING | Offering amount: $75,000,000 | Bank: J.P. Morgan, Guggenheim Securities

Feb 25, 2026

424B5

REGISTERED OFFERING

Jul 30, 2025

424B5

SHELF OFFERING | Warrants exercise price: $2.64 | Bank: Leerink Partners, Guggenheim Securities

Jul 29, 2025

424B5

SHELF OFFERING | Shares amount: 17,162,472 | Share price: $8.74 | Offering amount: $150,000,005.00

Feb 14, 2024

424B5

PENDING OFFERING | PENDING OFFERING | Share price: $7.831

Feb 13, 2024

Registrations

TYPE

HEADLINE

FILED AT

Proxies

TYPE

HEADLINE

FILED AT

Ownerships

TYPE

HEADLINE

FILED AT

Other

TYPE

HEADLINE

FILED AT